{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"OtherAbstract": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "SpaceFlightMission": [], "KeywordList": [], "InvestigatorList": [], "PMID": "9164584", "DateCompleted": {"Year": "1997", "Month": "07", "Day": "30"}, "DateRevised": {"Year": "2019", "Month": "07", "Day": "12"}, "Article": {"Language": ["eng"], "ArticleDate": [], "ELocationID": [], "Journal": {"ISSN": "0091-3057", "JournalIssue": {"Volume": "57", "Issue": "1-2", "PubDate": {"Year": "1997", "Season": "May-Jun"}}, "Title": "Pharmacology, biochemistry, and behavior", "ISOAbbreviation": "Pharmacol Biochem Behav"}, "ArticleTitle": "Majonoside-R2, a major constituent of Vietnamese ginseng, attenuates opioid-induced antinociception.", "Pagination": {"StartPage": "285", "EndPage": "291", "MedlinePgn": "285-91"}, "Abstract": {"AbstractText": ["The effects of majonoside-R2 on antinociceptive responses caused by the mu-opioid receptor agonist morphine and the selective kappa-opioid receptor agonist U-50, 488H were examined by the tail-pinch test in mice. Intraperitoneal (IP) or intracerebroventricular (ICV) injection of majonoside-R2 (3.1-6.2 mg/kg, IP or 5-10 micrograms/mouse, ICV) and diazepam (0.1-0.5 mg/kg, IP or 0.5-1.0 microgram/mouse, ICV), as well as an opioid receptor antagonist naloxone (2 mg/kg, IP or 5 micrograms/mouse, ICV), dose-dependently attenuated the antinociception caused by subcutaneously administered morphine and U-50,488H. Moreover, when co-administered ICV or intrathecally (IT) with morphine (4 micrograms/mouse) or U-50,488H (60 micrograms/mouse), majonoside-R2 (5-20 micrograms/mouse) also exhibited antagonism against the antinociceptive action of these opioid receptor agonists in the tail-pinch test. The inhibitory effects of majonoside-R2 (10 micrograms/mouse, ICV) and diazepam (1 microgram/mouse, ICV) were reversed by flumazenil (2.5 micrograms/mouse, ICV), a selective benzodiazepine receptor antagonist, and picrotoxin (0.25 microgram/mouse, ICV), a GABA-gated chloride channel blocker. These results suggest that majonoside-R2 attenuates the opioid-induced antinociception by acting at the spinal and supraspinal levels, and that the GABAA receptor complex at the supraspinal level is involved in the effect of ICV administered majonoside-R2."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, Research Institute for Wakan-Yaku (Oriental Medicines), Toyama Medical and Pharmaceutical University, Japan."}], "LastName": "Huong", "ForeName": "N T", "Initials": "NT"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Matsumoto", "ForeName": "K", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Yamasaki", "ForeName": "K", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Duc", "ForeName": "N M", "Initials": "NM"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Nham", "ForeName": "N T", "Initials": "NT"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Watanabe", "ForeName": "H", "Initials": "H"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Pharmacol Biochem Behav", "NlmUniqueID": "0367050", "ISSNLinking": "0091-3057"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Analgesics"}, {"RegistryNumber": "0", "NameOfSubstance": "Analgesics, Opioid"}, {"RegistryNumber": "0", "NameOfSubstance": "GABA Antagonists"}, {"RegistryNumber": "0", "NameOfSubstance": "Ginsenosides"}, {"RegistryNumber": "0", "NameOfSubstance": "Pyrrolidines"}, {"RegistryNumber": "0", "NameOfSubstance": "Receptors, Opioid, kappa"}, {"RegistryNumber": "0", "NameOfSubstance": "Receptors, Opioid, mu"}, {"RegistryNumber": "0", "NameOfSubstance": "Saponins"}, {"RegistryNumber": "67198-13-4", "NameOfSubstance": "3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer"}, {"RegistryNumber": "76I7G6D29C", "NameOfSubstance": "Morphine"}, {"RegistryNumber": "81534-63-6", "NameOfSubstance": "majonoside R2"}, {"RegistryNumber": "Q3JTX2Q7TU", "NameOfSubstance": "Diazepam"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Analgesics"}, {"QualifierName": ["antagonists & inhibitors"], "DescriptorName": "Analgesics, Opioid"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Diazepam"}, {"QualifierName": ["pharmacology"], "DescriptorName": "GABA Antagonists"}, {"QualifierName": [], "DescriptorName": "Ginsenosides"}, {"QualifierName": [], "DescriptorName": "Injections, Intraventricular"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Mice, Inbred Strains"}, {"QualifierName": ["antagonists & inhibitors"], "DescriptorName": "Morphine"}, {"QualifierName": [], "DescriptorName": "Pain Measurement"}, {"QualifierName": ["chemistry"], "DescriptorName": "Panax"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Pyrrolidines"}, {"QualifierName": ["agonists"], "DescriptorName": "Receptors, Opioid, kappa"}, {"QualifierName": ["agonists"], "DescriptorName": "Receptors, Opioid, mu"}, {"QualifierName": ["isolation & purification", "pharmacology"], "DescriptorName": "Saponins"}, {"QualifierName": [], "DescriptorName": "Vietnam"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "1997", "Month": "5", "Day": "1"}, {"Year": "1997", "Month": "5", "Day": "1", "Hour": "0", "Minute": "1"}, {"Year": "1997", "Month": "5", "Day": "1", "Hour": "0", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["9164584", "10.1016/s0091-3057(96)00348-6", "S0091-3057(96)00348-6"]}}]}